ATE456367T1 - Proteinkinase c inhibitoren - Google Patents

Proteinkinase c inhibitoren

Info

Publication number
ATE456367T1
ATE456367T1 AT04102054T AT04102054T ATE456367T1 AT E456367 T1 ATE456367 T1 AT E456367T1 AT 04102054 T AT04102054 T AT 04102054T AT 04102054 T AT04102054 T AT 04102054T AT E456367 T1 ATE456367 T1 AT E456367T1
Authority
AT
Austria
Prior art keywords
beta
protein kinase
inhibitors
isozyme
present
Prior art date
Application number
AT04102054T
Other languages
English (en)
Inventor
William Francis Heath Junior Heath
John Hampton Mcdonald Iii
Michael Paal
Gerd Ruhter
Schotten Theo
Wolfgang Stenzel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/324,948 external-priority patent/US5545636A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE456367T1 publication Critical patent/ATE456367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04102054T 1993-12-23 1994-12-14 Proteinkinase c inhibitoren ATE456367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17374193A 1993-12-23 1993-12-23
US08/324,948 US5545636A (en) 1993-12-23 1994-10-18 Protein kinase C inhibitors

Publications (1)

Publication Number Publication Date
ATE456367T1 true ATE456367T1 (de) 2010-02-15

Family

ID=26869484

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95904892T ATE290378T1 (de) 1993-12-23 1994-12-14 Proteinkinase c-inhibitoren
AT04102054T ATE456367T1 (de) 1993-12-23 1994-12-14 Proteinkinase c inhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95904892T ATE290378T1 (de) 1993-12-23 1994-12-14 Proteinkinase c-inhibitoren

Country Status (12)

Country Link
US (3) US5668152A (de)
EP (2) EP0817627B1 (de)
JP (4) JP3998261B2 (de)
AT (2) ATE290378T1 (de)
AU (1) AU1339895A (de)
CA (1) CA2179650C (de)
DE (1) DE69434294T2 (de)
DK (1) DK0817627T3 (de)
ES (1) ES2236702T3 (de)
PT (1) PT817627E (de)
SI (1) SI0817627T1 (de)
WO (1) WO1995017182A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919946A (en) * 1996-03-20 1999-07-06 Eli Lilly And Company Synthesis of indolylmaleimides
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603285D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603284D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
PT1064279E (pt) * 1998-03-17 2003-10-31 Hoffmann La Roche Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular
DE19838506C2 (de) * 1998-05-04 2000-08-31 Asta Medica Ag Indolderivate und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
HUP0102563A3 (en) 1998-05-04 2003-04-28 Zentaris Gmbh Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
AU5567000A (en) * 1999-06-24 2001-01-09 Toray Industries, Inc. Alpha1b-adrenergic receptor antagonists
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
AU2576901A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
US6743785B2 (en) 1999-12-16 2004-06-01 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
EP1242420A2 (de) 1999-12-16 2002-09-25 Eli Lilly And Company Mittel und verfahren zur behandlung von proliferativen erkrankungen
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
AU783615B2 (en) 2000-05-11 2005-11-17 Consejo Superior De Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase GSK-3
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
WO2002002116A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
BR0116468A (pt) 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
EP1513830A1 (de) * 2002-06-05 2005-03-16 Janssen Pharmaceutica N.V. Bisindolyl-maleinimidderivate als kinase-inhibitoren
JP2005531607A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤として置換ピロリン
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
WO2005041953A1 (en) * 2003-10-24 2005-05-12 Eli Lilly And Company Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
KR100941205B1 (ko) 2005-02-09 2010-02-10 아르퀼 인코포레이티드 말레이미드 유도체, 약제학적 조성물 및 암을 치료하는방법
EP1877424A4 (de) * 2005-04-11 2010-09-29 Pharmagap Inc Inhibitoren von proteinkinasen und anwendungen davon
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
MX2008000463A (es) * 2005-07-11 2008-03-11 Novartis Ag Derivados de indolil-maleimida.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
CA2912546A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Compositions and methods for treatment of cancer
KR20100024494A (ko) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
EP2170870B1 (de) 2007-06-22 2014-03-05 ArQule, Inc. Pyrrolidinon-, pyrrolidin-2,5-dion-, pyrrolidin- und thiosuccinimidderivate, zusammensetzungen und verfahren zur behandlung von krebs
EP2240475B1 (de) 2007-12-20 2013-09-25 Novartis AG Als pi-3-kinase-inhibitoren verwendete thiazolderivate
WO2010019225A1 (en) * 2008-08-15 2010-02-18 Robert Shorr Pharmaceutical composition
KR20110084533A (ko) 2008-12-15 2011-07-25 일라이 릴리 앤드 캄파니 암의 치료를 위한 엔자스타우린
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
KR101461767B1 (ko) 2010-03-30 2014-11-13 노파르티스 아게 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
MX343706B (es) 2011-01-31 2016-11-18 Novartis Ag Derivados heterocíclicos novedosos.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
CN104203951B (zh) 2012-03-16 2016-11-02 生命医药公司 肝x受体调节剂
WO2013138568A1 (en) 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
WO2014085381A1 (en) 2012-11-29 2014-06-05 Novartis Ag Pharmaceutical combinations
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CN105979947A (zh) 2013-12-06 2016-09-28 诺华股份有限公司 α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN104398508B (zh) * 2014-11-28 2017-06-13 上海交通大学 双吲哚马来酰亚胺衍生物在制备治疗慢性粒细胞白血病药物中的应用
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN108883103A (zh) * 2015-12-02 2018-11-23 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
CN110218206B (zh) * 2016-06-01 2022-03-04 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN106146475B (zh) * 2016-06-01 2019-05-17 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
DE3942991A1 (de) * 1989-12-27 1991-07-04 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
EP0580609A1 (de) * 1991-03-22 1994-02-02 Xenova Limited Pharmazeutische xanthonderivate
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
AU3761393A (en) * 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
EP1449529A1 (de) 2004-08-25
US5668152A (en) 1997-09-16
ATE290378T1 (de) 2005-03-15
EP0817627A1 (de) 1998-01-14
EP0817627B1 (de) 2005-03-09
JP3998261B2 (ja) 2007-10-24
US5661173A (en) 1997-08-26
JP2005225896A (ja) 2005-08-25
PT817627E (pt) 2005-07-29
DE69434294T2 (de) 2005-12-29
SI0817627T1 (de) 2005-08-31
JP4490400B2 (ja) 2010-06-23
JP4365803B2 (ja) 2009-11-18
DE69434294D1 (de) 2005-04-14
CA2179650A1 (en) 1995-06-29
WO1995017182A1 (en) 1995-06-29
JP2005225895A (ja) 2005-08-25
CA2179650C (en) 2007-10-30
JPH09507066A (ja) 1997-07-15
EP1449529B1 (de) 2010-01-27
JP4369397B2 (ja) 2009-11-18
DK0817627T3 (da) 2005-06-06
ES2236702T3 (es) 2005-07-16
EP0817627A4 (de) 2002-07-17
HK1008183A1 (en) 1999-05-07
AU1339895A (en) 1995-07-10
US5672618A (en) 1997-09-30
JP2006316068A (ja) 2006-11-24

Similar Documents

Publication Publication Date Title
DE69434294D1 (de) Proteinkinase c-inhibitoren
DK0766682T3 (da) Proteinkinase-C-inhibitorer
CA2376596A1 (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
ATE234092T1 (de) 2-alkylpyrrolidine
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
AU2002366641A1 (en) Methods for inhibiting ocular processes
WO2003080566A3 (en) Hif hydroxylase inhibitors
AU7585598A (en) Raf kinase inhibitors
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
FI941411L (fi) Vaahdotuskammio, jossa on injektori
EP0590747A3 (de) Beta-6-N-Acetylglukosaminyltransferase, das Akzeptor-Molekül, Leukosialin und Verfahren zur Klonierung enzymatisch-aktiven Proteinen.
IT1240486B (it) Procedimento di ammollo enzimatico per pelli e pellami.
ATE206875T1 (de) Methode zur verbesserung der fortpflanzungsfähigkeit von ebern durch verwendung eines speziellen futters für zuchteber
WO1993015112A3 (en) COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FUNCTION
IL142220A0 (en) Method of treating viral hemorrhagic fever
DE3861462D1 (de) Gasfeuerzeugstruktur, geeignet zur andrueckmontage seiner hauptteile.
CA2153778A1 (en) Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
WO2001087239A3 (en) Methods of affecting laminin 5 processing
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
IL142255A0 (en) Method of treating heparin-induced thrombocytopenia
BR9801691B1 (pt) processo de desaromatização de hidrocarbonetos por adsorção.
WO2004017909A3 (en) Methods of reducing ischemic injury
EP0646651A3 (de) Verfahren zur Verbesserung der Lederbehandlung.
FI982630A0 (fi) Menetelmä 2,6-dimetyylinaftaleenin valmistamiseksi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties